Europe — EMA
Nalador (Sulprostone)
GNH USA supplies Nalador (Sulprostone), a prostaglandin analog for induction of labor, postpartum hemorrhage and peptic ulcer disease.
Request sourcing
What is Sulprostone?
Sulprostone, the active ingredient in Nalador, is a prostaglandin analog presented as an intravenous solution for intravenous use. It is employed to stimulate uterine contractions during labor induction, manage postpartum hemorrhage, and provide gastro‑protective effects in peptic ulcer disease.
GNH USA supplies Nalador as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
What is Sulprostone used for?
Nalador (sulprostone) acts as a prostaglandin analog influencing uterine smooth‑muscle tone and gastric mucosal protection.
Induction of labor: facilitates cervical ripening and uterine contractions to initiate delivery. Postpartum hemorrhage: enhances uterine contractility to reduce bleeding after delivery. Peptic ulcer disease: promotes gastric mucosal defense and reduces ulcer recurrence.
What are the side effects of Sulprostone?
Adverse reactions may occur with sulprostone administration.
Common Side Effects: - Nausea - Vomiting - Diarrhea - Abdominal pain - Flushing - Headache
Serious or Rare Side Effects: - Uterine hyperstimulation - Severe hypotension - Bronchospasm - Allergic reactions (rash, anaphylaxis) - Myocardial ischemia - Pulmonary edema
What precautions apply to Sulprostone?
Use of sulprostone requires careful clinical monitoring.
Monitor uterine activity: observe for excessive contractions. Assess maternal hemodynamics: watch blood pressure and heart rate. Use with caution in cardiovascular disease: risk of hypotension. Avoid in known hypersensitivity to prostaglandins. Adjust in renal or hepatic impairment: consider reduced clearance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.
What does Sulprostone interact with?
Sulprostone may interact with several drug classes.
Major Interactions (Avoid): - NSAIDs: may diminish uterotonic effect. - Anticoagulants: increased risk of bleeding. - Oxytocin: additive uterine stimulation leading to hyperstimulation.
Moderate Interactions (Monitor Closely): - Beta‑agonists: may counteract uterine contraction. - Calcium channel blockers: may reduce efficacy. - ACE inhibitors: potential additive hypotensive effect. - Diuretics: may exacerbate fluid loss. - Antihypertensives: monitor blood pressure closely.
